About Prescribed Retatrutide

What this site is

Prescribed Retatrutide is an independent editorial project that publishes data-forward summaries of the peer-reviewed and registered-trial literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name — "prescribed" — is an editorial position relative to the compound's subject matter, not a claim about services offered. Retatrutide is an investigational drug; this site does not prescribe, dispense, recommend, or facilitate access to it. The editorial framing is a reference to the drug's clinical context — it is in trials aimed at establishing whether it should eventually be prescribed — not a representation that we provide prescriptions or clinical services.

Why data-forward

The retatrutide literature is unusually quantitative. Phase 2 trials reported specific mean body-weight percentage changes, HbA1c deltas, liver-fat reductions by MRI-PDFF, and heart-rate increments by dose arm. That precision is the literature — and burying it behind hedged prose obscures the most valuable part of the record.

The data-forward-analyst voice used on this site reads the trial figures the way an analyst reads a spec sheet: dose on the row, endpoint on the column, source in the margin. The goal is to surface exactly what was measured, at exactly what dose, in exactly which population, with exactly which result — and to leave the unanswered questions (long-term outcomes, post-approval availability, head-to-head comparisons) visibly blank rather than glossed over.

This approach is not advocacy for retatrutide's use. The compound is investigational. The cardiometabolic safety profile has real unresolved dimensions, including a dose-dependent heart-rate increase, GI-event driven discontinuation at 18% at the highest dose, and long-term outcome trials still running. Those figures are in this record too.

What this site does not do

• Does not prescribe or recommend any use of retatrutide.
• Does not facilitate access to retatrutide through any channel.
• Does not employ or represent any clinician, pharmacist, or healthcare provider.
• Does not link to, endorse, or advertise vendors of research-labeled retatrutide.
• Does not provide medical advice of any kind.
• Does not offer consultation services.

If you are seeking retatrutide through a clinical trial, ClinicalTrials.gov is the authoritative source for trial enrollment. If you have received a retatrutide prescription as part of a registered trial, your prescribing investigator is the appropriate source for clinical guidance.

Editorial standards

Every quantitative claim on this site carries an inline citation to its published source. Claims that are not in the peer-reviewed record are not written. Anecdotal community reports — on the effects page — are clearly labeled as anecdotal, not clinical evidence, and are kept separate from trial findings. No invented citations, no misattributed figures, no speculative efficacy claims presented as established. The Retatrutide references page indexes every source used across the site with DOI and URL.